This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Motzer RJ , Escudier B , McDermott DF , George S , Hammers HJ , Srinivas S , Tykodi SS , Sosman JA , Procopio G , Plimack ER , Castellano D , Choueiri TK , Gurney H , Donskov F , Bono P , Wagstaff J , Gauler TC , Ueda T , Tomita Y , Schutz FA , Kollmannsberger C , Larkin J , Ravaud A , Simon JS , Xu LA , Waxman IM , Sharma P , CheckMate Investigators
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
N Engl J Med. 2015 Nov 5;373(19) :1803-13
PMID: 26406148 PMCID: PMC5719487 URL: http://www.ncbi.nlm.nih.gov/pubmed/26406148
AbstractBACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P</=0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
NotesMotzer, Robert J Escudier, Bernard McDermott, David F George, Saby Hammers, Hans J Srinivas, Sandhya Tykodi, Scott S Sosman, Jeffrey A Procopio, Giuseppe Plimack, Elizabeth R Castellano, Daniel Choueiri, Toni K Gurney, Howard Donskov, Frede Bono, Petri Wagstaff, John Gauler, Thomas C Ueda, Takeshi Tomita, Yoshihiko Schutz, Fabio A Kollmannsberger, Christian Larkin, James Ravaud, Alain Simon, Jason S Xu, Li-An Waxman, Ian M Sharma, Padmanee eng Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2015/09/26 06:00 N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.